Biotech RadarJobs updated

COMPANY

Beam Therapeutics

HQ: Cambridge, MA source · beamtx.com ↗ · New England

Clinical Phase 2

Beam Therapeutics is listed on ClinicalTrials.gov as the lead sponsor of 6 studies; the most recently updated is “A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)” (Phase 1, Phase 2, recruiting), in Alpha 1-Antitrypsin Deficiency. From public records Source · Oct 12, 2026

Keywords: LNP alpha-1 antitrypsin deficiency Sickle Cell Disease Hemoglobinopathy Glycogen Storage Disease Type Ia Lymphoblastic Lymphoma T-Cell Lymphoblastic Leukemia/Lymphoma Lymphoblastic Leukemia Long-Term Follow-up Study of patients who received BEAM-101 BEAM-103 BEAM-101 BEAM-201

Location: Cambridge, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

$1.0BRaised (2 yrs)6Trials (company is sponsor)

Timeline

  1. Raise Private placement: $500M (total, as published), announced Feb 24, 2026. Source: company release on GlobeNewswire. source ↗
  2. Trial start —: A Long-term Follow-up Study in Patients Who Received BEAM-101 source ↗
  3. Trial start 1: This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects source ↗
  4. Raise Follow-on offering: $500M (total, as published), announced Mar 10, 2025. Source: SEC filing. source ↗
  5. Trial start 1: A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa) source ↗
  6. Trial start Phase 1/Phase 2: A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) source ↗
  7. Trial start Phase 1/Phase 2: A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) source ↗
  8. Trial start Phase 1/Phase 2: BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $1.0B. Last 2 years.

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT06389877A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)Phase 1/Phase 2RecruitingJun 19, 20242028-05 (estimated)
NCT07373639A Long-term Follow-up Study in Patients Who Received BEAM-101Not listedRecruitingDec 15, 2025Feb 12, 2043 (estimated)
NCT07304791This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects1RecruitingOct 27, 2025Jan 29, 2026 (estimated)
NCT05456880BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell DiseasePhase 1/Phase 2Active, not recruitingAug 30, 20222028-02 (estimated)
NCT06735755A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)1RecruitingDec 6, 2024Dec 30, 2027 (estimated)
NCT05885464A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)Phase 1/Phase 2Active, not recruitingMay 25, 20232026-12 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback